3.

Univariate analysis of association of clinicopathologic factors with PFS and OS (n=259)

Variables	PFS				OS
	HR	95% CI	P		HR	95% CI	P
PFS, progression-free survival; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, poorly differentiated; SRC, signet ring cell carcinoma; LN, lymph node; UNL, upper normal limit; WBC, white blood cells; ALP, alkaline phosphatase; AMC, Asan Medical Center; qPCR, quantitative polymerase chain reaction; gCN, gene copy number; HR, hazard ratio; 95% CI, 95% confidence interval.
Female	1.04	0.78−1.40	0.785		0.98	0.74−1.30	0.904
Age ≥65 years	0.96	0.70−1.31	0.782		1.26	0.95−1.68	0.108
ECOG PS 2−4	1.70	1.12−2.58	0.013		2.60	1.80−3.77	<0.001
Borrmann type: IV	1.89	1.32−2.70	<0.001		1.75	1.24−2.46	0.001
Histology: PD/SRC/mucinous	1.15	0.86−1.53	0.343		1.11	0.85−1.45	0.434
No gastrectomy	0.61	0.45−0.82	0.001		0.54	0.41−0.72	<0.001
Peritoneal metastasis	0.97	0.74−1.27	0.828		1.18	0.92−1.51	0.206
Liver metastasis	1.17	0.87−1.57	0.299		1.13	0.86−1.48	0.377
Lung metastasis	1.90	1.06−3.41	0.031		1.82	1.02−3.26	0.044
Distant LN metastasis	1.00	0.77−1.30	0.990		0.92	0.71−1.16	0.429
Bone metastasis	2.33	1.47−3.68	<0.001		3.36	2.17−5.20	<0.001
Hemoglobin ≤UNL	0.82	0.61−1.09	0.167		0.99	0.75−1.31	0.957
WBC ≥10,000/mm3	1.00	0.67−1.48	0.988		1.16	0.80−1.68	0.427
Platelet ≤150×103/mm3	1.01	0.67−1.54	0.955		1.11	0.75−1.64	0.609
Albumin ≤3.3 g/dL	1.52	1.15−2.01	0.003		2.14	1.65−2.79	<0.001
ALP >120 IU/L	1.90	1.38−2.63	<0.001		1.94	1.43−2.62	<0.001
Total bilirubin >1.2 mg/dL	1.27	0.81−1.98	0.293		1.24	0.81−1.89	0.315
Risk groups by AMC prognostic model
Good	1.00				1.00
Moderate	1.14	0.85−1.53	0.369		1.38	1.04−1.83	0.024
Poor	2.14	1.45−3.15	<0.001		3.19	2.23−4.57	<0.001
MET qPCR ≥5 gCN	0.77	0.43−1.37	0.766		0.66	0.37−1.20	0.172